- Home
- RIG vs LEGN Comparison
RIG vs LEGN Comparison
Compare RIG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIG | LEGN |
|---|---|---|
| Founded | 1926 | 2014 |
| Country | Switzerland | United States |
| Employees | 5600 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.9B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RIG | LEGN |
|---|---|---|
| Price | $6.53 | $18.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $6.70 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 33.5M | 1.2M |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,973,000,000.00 | N/A |
| Revenue This Year | N/A | $42.19 |
| Revenue Next Year | N/A | $33.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.08 | $16.24 |
| 52 Week High | $7.14 | $45.30 |
Technical Indicators
Market Signals| Indicator | RIG | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 48.10 |
| Support Level | $5.98 | $17.46 |
| Resistance Level | $7.05 | $19.36 |
| Average True Range (ATR) | 0.34 | 0.71 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 46.05 | 51.69 |
Price Performance
Historical ComparisonAbout RIG Transocean Ltd (Switzerland)
Transocean Ltd. is an international provider of offshore contract drilling services for oil and gas wells. The company provides mobile offshore drilling rigs, related equipment, and crews to support the drilling of oil and gas wells. Its fleet mainly consists of offshore rigs, including drillships, semisubmersibles, and jackups.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.